UroGen Pharma (URGN) Presented Real-World Study of JELMYTO at 2025 American Society of Clinical Oncology

UroGen Pharma Ltd. (NASDAQ:URGN) is one of the Stocks With Huge Catalysts on the HorizonOn June 2, UroGen Pharma Ltd. (NASDAQ:URGN) presented its uTRACT Registry study design at the 2025 American Society of Clinical Oncology. The main focus was on presenting the real-world study of JELMYTO, which is a treatment for adults with low-grade upper tract urothelial carcinoma.

The presentation highlighted that the uTRACT Registry is taking place across 22 sites in the United States and is tracking the use of JELMYTO for patients with cancer of the lining of the upper urinary tract. Management noted that as of May 2025, 274 patients had been enrolled to reach 400 registries. The study will observe patients over three years, and the data is expected to provide key information about the treatment pattern, safety, effectiveness, and outcomes like disease response and time to recurrence. The treatment is under review by the FDA, and management expects the study to present valuable insights.

UroGen Pharma (URGN) Presented Real-World Study of JELMYTO at 2025 American Society of Clinical Oncology

A scientist examining a sample of hydrogel in a laboratory setting.

UroGen Pharma Ltd. (NASDAQ:URGN) is a biopharmaceutical company focused on developing treatments for cancers and urologic diseases.

While we acknowledge the potential of URGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than URGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.